Mouse Model News and Research

RSS

Thymosin beta 4 reduces brain tissue damage, improves brain function in rats: Research paper

RegeneRx Biopharmaceuticals, Inc. announced today that in a preclinical research paper published in the May 2010 issue of the Journal of Neurosurgery, (online ahead of publication), scientists found that the systemic administration of thymosin beta 4, or Tβ4, significantly reduced brain tissue damage and improved brain function in rats with traumatic brain injury, or TBI.

24 May 2010

Study: Th1 cells play a vital role in pathogenesis of immune-mediated diseases

Current research suggests that T helper-type 1 (Th1) cells, previously thought to mediate autoimmunity, may actual inhibit the development of experimental immune encephalomyelitis (EAE), a mouse model of multiple sclerosis (MS), by suppressing Th17 cells.

24 May 2010

IGF1 drug improves nerve cell communication in PMS mouse model

Researchers from Mount Sinai School of Medicine have identified a drug that improves communication between nerve cells in a mouse model of Phelan-McDermid Syndrome (PMS).

21 May 2010

Researchers identify drug that improves communication between nerve cells in Phelan-McDermid Syndrome

Researchers from Mount Sinai School of Medicine have identified a drug that improves communication between nerve cells in a mouse model of Phelan-McDermid Syndrome (PMS). Behavioral symptoms of PMS fall under the autism spectrum disorder category. The research will be presented Friday at the International Meeting for Autism Research (IMFAR) in Philadelphia.

21 May 2010

Lentigen receives NIH STTR grant for Hunter syndrome lentiviral gene therapy

Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) small business technology transfer (STTR) grant for a program on "Lentiviral Gene Therapy for Mucopolysaccharidosis."

19 May 2010

Combination therapy proves to be effective treatment for lethal form of leukemia: Research

New research discovers a combination of drugs that may prove to be a more effective treatment for a lethal form of leukemia. The study, published by Cell Press in the May issue of the journal Cancer Cell, reports that the new therapeutic strategy effectively targets notoriously intractable leukemia stem cells that often escape standard treatment and are a main factor in disease relapse.

18 May 2010

NanoViricides signs Research Agreement with UCSF for testing anti-HIV drug candidates

NanoViricides, Inc., announced that it has signed a Research Agreement with the University of California, San Francisco for testing of its anti-HIV drug candidates. Cheryl Stoddart, PhD, Assistant Professor in the UCSF Division of Experimental Medicine, will be the Principal Investigator.

17 May 2010

UC researchers explore dynamics of bacterial evolution

Researchers found that as dominant members of the population surrendered to host immune defenses, they were replaced by a hyperaggressive, mutant minority population that thrived and took over the abandoned community to become the new majority.

15 May 2010

NanoViricides signs research and development agreement with Dr. Ken S. Rosenthal's laboratory

NanoViricides, Inc., reports that it has signed a research and development agreement with Dr. Ken S. Rosenthal's laboratory at Northeastern Ohio Universities Colleges of Medicine and Pharmacy.

14 May 2010

Each melanoma cell capable of cancer stem cell behavior: Study

Scientists at The Wistar Institute offer a new explanation for the persistent ability of melanoma cells to self-renew, one of the reasons why melanoma remains the deadliest form of skin cancer. The concept of the "dynamic stemness" of melanoma can explain why melanoma cells behave like both conventional tumor cells and cancer stem cells.

14 May 2010

Novel vaccines for deadly diseases to be presented at AAPS' NBC

Novel vaccines for diseases ranging from the flu to HIV highlight a week's worth of biotechnology research at the American Association of Pharmaceutical Scientists' National Biotechnology Conference. Scientists from academia, industry, and government will gather at the Hilton San Francisco Union Square Sunday, May 16 -Thursday, May 20 to share research and advances in biotherapeutics.

14 May 2010

Key mechanisms for delivery of LNP-encapsulated siRNAs to the liver

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the publication of pre-clinical research in the journal Molecular Therapy revealing key mechanisms related to the systemic delivery of RNAi therapeutics using lipid nanoparticles (LNPs).

12 May 2010

Mutations in STRAD-alpha gene can cause PMSE syndrome in Amish children: Penn researchers

So often the rare informs the common. Penn researchers investigating a regulatory protein involved in a rare genetic disease have shown that it may be related to epileptic and autistic symptoms in other more common neurological disorders.

12 May 2010

Increased cholesterol levels can affect microenvironment of bone marrow

Increased cholesterol levels are being increasingly recognised as risk factors for the onset and progression of several cancers. Now researchers in Portugal show that high levels of cholesterol can affect the microenvironment of the bone marrow, so that more cells move from the bone marrow to peripheral, circulating blood.

11 May 2010

Winners of IOF-Servier Young Investigator Research Grant

The International Osteoporosis Foundation (IOF) has awarded the IOF-Servier Young Investigator Research Grant to co-winners Dr. Frank DeVries, University of Utrecht, the Netherlands, and Dr. Davide Ruffoni, Institute for Biomechanics, ETH Zurich, Switzerland.

11 May 2010

Study: PDE5 inhibitors may increase permeability of blood brain barrier to Herceptin

New research by scientists at Cedars-Sinai's Maxine Dunitz Neurosurgical Institute suggests that a drug currently approved to treat erectile dysfunction may significantly enhance the delivery of the anti-cancer drug Herceptin to certain hard-to-treat brain tumors.

10 May 2010

Novel imaging techniques improve post heart attack survival rates in mouse model

Human adult stem cells injected around the damage caused by a heart attack survived in the heart and improved its pumping efficiency for a year in a mouse model, researchers at The University of Texas MD Anderson Cancer Center report online ahead of publication in Circulation Research.

10 May 2010

Closer to understanding age-related memory loss and drug to boost memory

The world's scientific community may be one step closer to understanding age-related memory loss, and to developing a drug that might help boost memory. In an editorial published May 7 in Science, J. David Sweatt, Ph.D., chair of the University of Alabama at Birmingham (UAB) Department of Neurobiology, says that drugs known as histone deacetylase inhibitors are showing great promise in stopping memory loss - and even in boosting the formation of memory in animal models.

7 May 2010

Pharmacyclics reports total GAAP revenues of $2.1 million for third-quarter fiscal 2010

Pharmacyclics, Inc. today reported financial results for its third quarter ended March 31, 2010.

6 May 2010

Acceleron Pharma commences Phase 2 clinical trial of ACE-031 protein therapeutic in DMD patients

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the initiation of a Phase 2 clinical trial with ACE-031 in patients with Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease. ACE-031 is an investigational protein therapeutic that builds muscle and increases strength by inhibiting signaling of a cell surface receptor called the activin receptor type IIB (ActRIIB).

5 May 2010

Mouse Model News and Research

Thymosin beta 4 reduces brain tissue damage, improves brain function in rats: Research paper

Study: Th1 cells play a vital role in pathogenesis of immune-mediated diseases

IGF1 drug improves nerve cell communication in PMS mouse model

Researchers identify drug that improves communication between nerve cells in Phelan-McDermid Syndrome

Lentigen receives NIH STTR grant for Hunter syndrome lentiviral gene therapy

Combination therapy proves to be effective treatment for lethal form of leukemia: Research

NanoViricides signs Research Agreement with UCSF for testing anti-HIV drug candidates

UC researchers explore dynamics of bacterial evolution

NanoViricides signs research and development agreement with Dr. Ken S. Rosenthal's laboratory

Each melanoma cell capable of cancer stem cell behavior: Study

Novel vaccines for deadly diseases to be presented at AAPS' NBC

Key mechanisms for delivery of LNP-encapsulated siRNAs to the liver

Mutations in STRAD-alpha gene can cause PMSE syndrome in Amish children: Penn researchers

Increased cholesterol levels can affect microenvironment of bone marrow

Winners of IOF-Servier Young Investigator Research Grant

Study: PDE5 inhibitors may increase permeability of blood brain barrier to Herceptin

Novel imaging techniques improve post heart attack survival rates in mouse model

Closer to understanding age-related memory loss and drug to boost memory

Pharmacyclics reports total GAAP revenues of $2.1 million for third-quarter fiscal 2010

Acceleron Pharma commences Phase 2 clinical trial of ACE-031 protein therapeutic in DMD patients

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News